Dissertation > Excellent graduate degree dissertation topics show

Variation of Circulating Platelet Microparticles and Endothelial Microparticles in Patients with Chronic Kidney Disease

Author: ZhangShuHua
Tutor: LuGuoYuan
School: Suzhou University
Course: Nephrology
Keywords: platelet microparticles endothelial microparticles microparticles chronic kidney disease
CLC: R692
Type: Master's thesis
Year: 2009
Downloads: 46
Quote: 0
Read: Download Dissertation

Abstract


Objective Compare the levels of PMPs、GMP140、EMPs and vWF in patients with chronic kidney disease and in normal control group, to explore the significance of the PMPs and EMPs in chronic kidney disease.Methods From February 2007 to June 2008, 72 cases of patients with chronic kidney disease who were hospitalized in the First Affiliated Hospital of Suzhou University were enrolled in this study (Definition and phases were based on K / DOQI chronic kidney disease clinical practice guidelines) ,20 cases of healthy controls were also enrolled. Circulating PMPs and EMPs were numerated by flow cytometry;GMP140 and vWF were measured by the enzyme-linked immunosorbent assay; The blood pressure, height and weight of all subjects were measured also.The Cockcroft-Gault formula to calculate creatinine clearance (Ccr (ml / min) = [(140 - age)×weight×(0.85 for women)] / (72×Scr))was used; Fasting venous blood samples were extracted to detect hemoglobin, serum creatinine, blood cholesterol, blood glucose; Urinary protein was detected by radioimmunoassay.Results1 Plasma levels of PMPs and GMP140 were significantly higher in CKD patients than that of in controls(P<0.05).2 Plasma levels of PMPs and GMP140 in CKD patients among different clinical classification groups: The levels of PMPs in nephritic syndrome group and chronic glomerulonephritis group were significantly higher than that of in control group(P<0.01,P<0.05),The level of PMPs in nephritic syndrome group was significantly higher than that of in hypertensive renal disease group(P <0.05),Other groups had no significant difference(P>0.05).The levels of GMP140 in all groups were significantly higher than that of in control group(P<0.01),The level of GMP140 in nephritic syndrome group was significantly higher than that of in Lupus nephropathy group, Diabetic Nephropathy group and hypertensive renal disease group(P<0.01,P<0.05), The level of GMP140 in chronic glomerulonephritis group was significantly higher than that of in Diabetic Nephropathy group(P<0.01).3 Plasma levels of PMPs and GMP140 in different stages of CKD: The level of PMPs in stage I was significantly higher than stage IV(P <0.05); Other stages had no significant difference(P >0.05). The level of GMP140 in different stages had no significant difference(P >0.05).4 As for PMPs, a positive correlation was found with blood pressure(r=0.39,P <0.05), no correlation was found among creatinine clearance(r=-0.15,P >0.05), 24h urinary protein(r=0.18,P >0.05), hemoglobin(r=-0.21,P >0.05), cholesterol(r=0.10,P >0.05),GMP140 has a positive correlation with PMPs(r=0.31,P <0.05).5 Plasma levels of EMPs and vWF were significantly higher in CKD patients than that of in controls(P<0.01).6 Plasma levels of EMPs and vWF in different clinical classification groups were significantly higher than that of in control group(P<0.01,P<0.05); The level of EMPs in nephritic syndrome group was significantly higher than that of in hypertensive renal disease group(P<0.05).Meanwhile, the level of vWF in nephritic syndrome group was remarkable higher than that of in hypertensive renal disease group and chronic glomerulonephritis group.Other groups had no significant difference(P >0.05).7 In different stages of CKD, the level of EMPs in stage I was significantly higher than stage IV(P<0.05), The level of vWF in different stages had no significant difference(P>0.05).8 As for EMPs, a positive correlation was found with blood pressure(r=0.52,P <0.01), no correlation was found among creatinine clearance(r=-0.12,P>0.05), 24h urinary protein(r=0.15,P>0.05), hemoglobin(r=-0.22,P>0.05), cholestero(lr=0.07,P>0.05). vWF has a positive correlation with EMPs(r=0.41,P<0.05).Conclusion1 Patients with chronic kidney disease have platelet activation and endothelial dysfunction. The platelet activation and endothelial dysfunction are participate in the pathophysiological process of the occurrence and development of chronic kidney disease.2 Hypertension is one of the important reasons for platelet activation and endothelial dysfunction in patients with chronic kidney disease.3 As a new marker, PMPs and EMPs can be used as a reflection of platelet activation and endothelial function.

Related Dissertations

  1. Bing- thick academic thought and clinical experience and empirical studies apply to turtle soups treatment of chronic kidney disease,R249.2
  2. Cystatin C assessment of chronic kidney disease, renal dysfunction clinical research,R692
  3. The Effect of Calycosin for ET-1/NO on the Damage of TNF-α in Human Umbilical Vein Endothelial Cells,R285
  4. The Effects of Insulin Resistance on Cardiovascular Lesions in Early Chronic Kidney Disease and Its Mechanisms,R54
  5. Compound Yiqihuoxue oral medicine treatment of diabetic nephropathy Systematic Review,R259
  6. Different renal function in patients with coronary percutaneous coronary intervention in patients with drug-eluting stent implantation bleeding and ischemic events after study,R541.4
  7. Comparative Study of Serum CystatinC, Serum Creatinine and Urine Microprotein in Glomerular Filtration Rate Measurement in Patients with Chronic Kidney Disease,R692
  8. Preliminary study of chronic kidney disease MIA syndrome TCM syndrome,R277.5
  9. Platelet microparticles on endothelial cell adhesion molecule expression,R541.4
  10. Different concentrations of uric acid on human renal tubular epithelial cells express intercellular adhesion molecule -1 in the,R692.6
  11. Influence of ACTH on Serum Lipid Levels and Renal Function in NZW Rabbits,R589.2
  12. Dai Xiwen treatment of chronic kidney disease Experience,R277.5
  13. No. Ⅰ Treatment of renal failure chronic kidney disease three wet spleen qi stasis clinical research,R277.5
  14. The Expression and Significance of Heparanase in Human Chronic Kidney Diseases Disease,R692
  15. The Expression and Significance of ICAM-1 in Human Primary Chronic Kidney Disease,R692.3
  16. Value of Interlobar Arterial Resistent Index for Early Diagnostic in Chronic Kidney Disease,R445.1
  17. Effects of Valsartan on Apoptosis of Diabetic Rat Kidney by JNK Pathway,R587.2
  18. Clinical Analysis of 158 Cases with Acute Kidney Injury on Chronic Kidney Disease,R692
  19. The Intervention of Valsartan on JNK Pathway and bcl-2 Factor in the Kidney Tissue of Diabetes Rats,R587.2
  20. Investigation into the Correlation between Urinary L-FABP and Tubulointerstitial Damage,R692

CLC: > Medicine, health > Surgery > Urology ( urinary and reproductive system diseases) > Kidney disease
© 2012 www.DissertationTopic.Net  Mobile